Papers
1
Total Citations
1,480
H-Index
1
About
Suping Li is a pioneering researcher in the field of DNA nanotechnology and targeted cancer therapy, whose work has fundamentally advanced the design of intelligent, stimuli-responsive drug delivery systems. Her most celebrated contribution is the development of a DNA nanorobot that functions as a cancer therapeutic in response to a molecular trigger in vivo, a breakthrough published in 2018 that has garnered over 1,480 citations. This study demonstrated the first autonomous, logic-gated nanorobot capable of precisely delivering payloads to tumor sites, marking a paradigm shift in how researchers approach the intersection of synthetic biology and oncology. Li’s broader research focuses on engineering programmable nanostructures for biomedical applications, including smart nanocarriers that respond to specific biological cues to minimize off-target effects. Her work has been recognized for its translational potential, influencing subsequent clinical trials and inspiring a new generation of DNA-based therapeutics. With a citation count exceeding 1,480 for her landmark paper alone, Suping Li stands as a key figure in nanomedicine, bridging molecular engineering and real-world cancer treatment.
Research Focus
Key Achievements
Top Papers
- 1